PT788356E - Metodo e composicoes para a inibicao de proteina-quinases. - Google Patents

Metodo e composicoes para a inibicao de proteina-quinases.

Info

Publication number
PT788356E
PT788356E PT95941340T PT95941340T PT788356E PT 788356 E PT788356 E PT 788356E PT 95941340 T PT95941340 T PT 95941340T PT 95941340 T PT95941340 T PT 95941340T PT 788356 E PT788356 E PT 788356E
Authority
PT
Portugal
Prior art keywords
independently represents
kinases
inhibition
protein
compositions
Prior art date
Application number
PT95941340T
Other languages
English (en)
Inventor
Neill A Giese
Nathalie Lokker
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Publication of PT788356E publication Critical patent/PT788356E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
PT95941340T 1994-10-28 1995-10-26 Metodo e composicoes para a inibicao de proteina-quinases. PT788356E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/332,597 US5795910A (en) 1994-10-28 1994-10-28 Method and compositions for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
PT788356E true PT788356E (pt) 2002-06-28

Family

ID=23298937

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95941340T PT788356E (pt) 1994-10-28 1995-10-26 Metodo e composicoes para a inibicao de proteina-quinases.

Country Status (14)

Country Link
US (3) US5795910A (pt)
EP (1) EP0788356B9 (pt)
JP (1) JPH10508024A (pt)
KR (1) KR970706812A (pt)
CN (1) CN1165481A (pt)
AT (1) ATE210439T1 (pt)
AU (1) AU706621B2 (pt)
CA (1) CA2203757A1 (pt)
DE (1) DE69524628T2 (pt)
DK (1) DK0788356T3 (pt)
ES (1) ES2170172T3 (pt)
PT (1) PT788356E (pt)
TW (1) TW467743B (pt)
WO (1) WO1996013259A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
CN1146747C (zh) * 1996-08-06 2004-04-21 精工爱普生株式会社 液晶显示装置和使用液晶显示装置的电子仪器
US6087352A (en) * 1998-08-17 2000-07-11 Trout; William E. Use of Zeranol to modulate reproductive cycles
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
WO2000033857A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils
CA2356622A1 (en) 1998-12-24 2000-07-06 Novation Pharmaceuticals Inc. Compounds which affect mrna stability and uses therefor
CA2380966A1 (en) * 1999-08-13 2001-02-22 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2004292314A (ja) * 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
US6565864B2 (en) 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
DE60218822T2 (de) * 2001-02-09 2007-07-12 Unilever N.V. Nahrungsmittel enthaltend sojaprotein und statin
WO2003041643A2 (en) * 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
FR2835252B1 (fr) * 2002-01-25 2005-08-05 Seppic Sa Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau
US7915306B2 (en) * 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
AU2003224672B2 (en) * 2002-03-08 2010-02-04 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
RU2312863C2 (ru) * 2002-04-17 2007-12-20 Тайсо Фармасьютикал Ко., Лтд. Тоник для роста волос
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2527130A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
KR101501870B1 (ko) 2003-08-27 2015-03-12 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
US20060079494A1 (en) * 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
JP5465006B2 (ja) 2006-08-11 2014-04-09 ユニベルシテ・ドウ・ストラスブール キナーゼおよびｈｓｐ９０の阻害剤として有用な大環状化合物
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8609640B2 (en) * 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
AU2008318690B2 (en) 2007-10-29 2015-08-13 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
WO2009075818A1 (en) 2007-12-07 2009-06-18 Eisai R & D Management Co., Ltd. Intermediates and methods for making zearalenone macrolide analogs
US20110190237A1 (en) * 2008-01-15 2011-08-04 Nexgenix Pharmaceuticals Macrocyclic Prodrug Compounds Useful as Therapeutics
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN101928700B (zh) * 2009-07-28 2012-05-02 北京恒宇视野生物科技有限公司 蛋白激酶pftk1单克隆抗体及其制备方法
CA2808866A1 (en) 2010-08-20 2012-02-23 The Hospital For Sick Children Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US10434085B2 (en) 2015-06-04 2019-10-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196019A (en) * 1964-04-06 1965-07-20 Purdue Research Foundation Anabolic and estrogenic compound and process of making
JPS6239558A (ja) * 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−シアノアクリル酸アミド誘導体
JPS6239523A (ja) * 1985-08-14 1987-02-20 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242923A (ja) * 1985-08-19 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
JPS6242925A (ja) * 1985-08-20 1987-02-24 Kanegafuchi Chem Ind Co Ltd 酵素阻害剤
US4842862A (en) * 1986-07-03 1989-06-27 International Minerals & Chemical Corp. Immunostimulating agents
GB9225396D0 (en) * 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
KR970706812A (ko) 1997-12-01
DE69524628D1 (de) 2002-01-24
CA2203757A1 (en) 1996-05-09
DK0788356T3 (da) 2002-03-18
EP0788356B1 (en) 2001-12-12
ES2170172T3 (es) 2002-08-01
WO1996013259A2 (en) 1996-05-09
ATE210439T1 (de) 2001-12-15
AU4278996A (en) 1996-05-23
AU706621B2 (en) 1999-06-17
US5674892A (en) 1997-10-07
US5795910A (en) 1998-08-18
US5728726A (en) 1998-03-17
EP0788356B9 (en) 2002-10-02
JPH10508024A (ja) 1998-08-04
TW467743B (en) 2001-12-11
EP0788356A2 (en) 1997-08-13
CN1165481A (zh) 1997-11-19
WO1996013259A3 (en) 1996-08-01
MX9703113A (es) 1998-06-30
DE69524628T2 (de) 2002-08-08

Similar Documents

Publication Publication Date Title
PT788356E (pt) Metodo e composicoes para a inibicao de proteina-quinases.
IT1283588B1 (it) Miscela sinergica di agenti stabilizzanti
DE69516866T2 (de) Stereochemische wortmanninderivate
DK0772603T3 (da) Substituerede pyrimidinforbindelser og deres anvendelse
ES2097653T3 (es) Nuevos derivados de desoxigalactonojirimicina.
BG103485A (en) Ketobanzamides as calpain inhibitors
EA199900373A2 (ru) Фармацевтические композиции
MX9700877A (es) Acondicionadores biodegradables, cuaternarios, del cabello y de la piel.
BG106585A (en) Kinase inhibitors as therapeutic agents
HN1997000149A (es) Derivados de 6 fenilpiridil 2 amina
ES2172083T3 (es) Composicion limpiadora antibacteriana ultrasuave para uso frecuente.
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DE69808099T2 (de) Substituierte 6-alkylphenanthridine
BG105710A (en) 5ht1 antagonists for antidepressant therapy
NO991230L (no) Trisykliske forbindelser for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
NZ336091A (en) Aqueous disinfecting cleaning composition
IL127575A0 (en) Prenyl transferase inhibitors
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
FI970318A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiitoreina käyttökelpoisia yhdisteitä
ES2085833B1 (es) Derivados de carboximetilidencicloheptimidazol y metodo para prepararlos.
DE69528984T2 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ECSP961773A (es) Metodos para minimizar la perdida osea x- 10208
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.